Barinthus Biotherapeutics plc (BRNS)
BRNS Stock Price Chart
Explore Barinthus Biotherapeutics plc interactive price chart. Choose custom timeframes to analyze BRNS price movements and trends.
BRNS Company Profile
Discover essential business fundamentals and corporate details for Barinthus Biotherapeutics plc (BRNS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Apr 2021
Employees
105.00
Website
https://www.barinthusbio.comCEO
William James Enright
Description
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
BRNS Financial Timeline
Browse a chronological timeline of Barinthus Biotherapeutics plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.28.
Earnings released on 30 Apr 2026
EPS came in at -$0.14 surpassing the estimated -$0.36 by +61.11%.
Earnings released on 13 Mar 2026
EPS came in at -$0.27 surpassing the estimated -$0.40 by +32.50%.
Earnings released on 7 Nov 2025
EPS came in at -$0.36 surpassing the estimated -$0.45 by +20.00%.
Earnings released on 7 Aug 2025
EPS came in at -$0.52 falling short of the estimated -$0.29 by -79.31%.
Earnings released on 7 May 2025
EPS came in at -$0.49 falling short of the estimated -$0.34 by -44.12%.
Earnings released on 20 Mar 2025
EPS came in at -$0.51 falling short of the estimated -$0.50 by -2.00%, while revenue for the quarter reached -$9.17m .
Earnings released on 6 Nov 2024
EPS came in at -$0.21 surpassing the estimated -$0.45 by +53.33%, while revenue for the quarter reached $14.97m .
Earnings released on 8 Aug 2024
EPS came in at -$0.43 falling short of the estimated -$0.42 by -2.38%.
Earnings released on 13 May 2024
EPS came in at -$0.40 surpassing the estimated -$0.64 by +37.50%.
Earnings released on 20 Mar 2024
EPS came in at -$0.45 surpassing the estimated -$0.55 by +18.18%, while revenue for the quarter reached $5.37m , beating expectations by +4.03k%.
Earnings released on 9 Nov 2023
EPS came in at -$0.37 surpassing the estimated -$0.62 by +40.32%.
Earnings released on 10 Aug 2023
EPS came in at -$0.62 falling short of the estimated -$0.59 by -5.08%, while revenue for the quarter reached $334.00k , missing expectations by -52.57%.
Earnings released on 31 Mar 2023
EPS came in at -$0.48 surpassing the estimated -$0.50 by +4.79%, while revenue for the quarter reached $468.00k , missing expectations by -66.57%.
Earnings released on 31 Dec 2022
EPS came in at -$0.56 falling short of the estimated -$0.43 by -32.27%, while revenue for the quarter reached $6.46m , beating expectations by +94.99%.
Earnings released on 30 Sept 2022
EPS came in at $0.22 surpassing the estimated -$0.38 by +157.22%, while revenue for the quarter reached $6.17m , missing expectations by -20.96%.
Earnings released on 30 Jun 2022
EPS came in at $0.41 surpassing the estimated -$0.32 by +227.18%, while revenue for the quarter reached $17.06m , beating expectations by +360.54%.
Earnings released on 31 Mar 2022
EPS came in at $0.07 , while revenue for the quarter reached $15.02m .
Earnings released on 31 Dec 2021
EPS came in at $0.07 surpassing the estimated -$0.31 by +121.94%, while revenue for the quarter reached $268.00k , missing expectations by -92.77%.
Earnings released on 30 Sept 2021
EPS came in at -$0.13 , while revenue for the quarter reached $19.00k .
BRNS Stock Performance
Access detailed BRNS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
